The purpose of this study is to determine whether a drug called KSI-301 is safe and effective in the treatment of age related macular degeneration (also known as wet-AMD), compared with the standard treatment aflibercept.

Wet-AMD is a condition that causes bleeding and swelling in the retina, the light sensitive tissue at the back of the eye, resulting in decreased vision. The standard treatment for wet-AMD is eye injections, with drugs such as aflibercept, every month or every other month to decrease the swelling in the retina.  These injections work by blocking a protein in the eye called vascular endothelial growth factor (VEGF).  When there is too much VEGF inside the eye because of wet-AMD, swelling can occur.

KSI-301 is an investigational drug which means it is a drug that is being tested and not yet approved by the FDA.  KSI-301 is designed by Kodiak Sciences, Inc. to decrease the fluid leakage and swelling in the retina blocking VEGF.  KSI-301 may last longer in the eye compared to the standard injection treatments currently available on the market and thus patients may need few injections of KSI-301 over time.

In this study, 1/2 of the participants will be given KSI-301 and the other half will receive aflibercept to treat their wet-AMD.  Particpants are assigned to these groups randomly.

If you would like more information on this study, please click on the link at the top of the page or go to www.clinicaltrials.gov.